LACTOLOGY FOUNDATION

Penthienate (ATC A03AB04) is a synthetic quaternary antimuscarinic used for functional gastrointestinal disorders, with an atropine‑like side‑effect and toxicity profile and very limited specific data on use in breastfeeding. In lactation, it should be considered a high‑caution or avoidable drug due to scant human data, possible maternal anticholinergic adverse effects, and theoretical risk of reduced milk production or infant anticholinergic symptoms.wikipedia+3

Drug class and indications

Penthienate belongs to ATC group A03AB04: synthetic anticholinergics, quaternary ammonium compounds used for functional gastrointestinal disorders. It reduces gastric motility and secretion and is indicated mainly for peptic ulcer, dyspepsia, and functional intestinal spasm.drugbank+4

Mechanism of action

As an antimuscarinic agent, penthienate competitively inhibits muscarinic acetylcholine receptors, producing effects similar to atropine on the gastrointestinal tract. It depresses gastric motility and secretion and reduces intestinal motor activity by blocking vagal stimulation.drugs.ncats+1

Pharmacokinetics and transfer into milk (theoretical)

Penthienate is a quaternary ammonium compound, which is generally more polar, less lipophilic and less able to cross lipid membranes than tertiary amines, theoretically limiting penetration into the central nervous system and breast milk. However, detailed published data on its absorption, plasma protein binding, volume of distribution, half‑life, and actual human milk levels are not available, so its lactation pharmacokinetics must be extrapolated from the class rather than drug‑specific evidence.precision.fda+2

Toxicology and safety profile (mother)

Toxicological information is sparse, but as a synthetic anticholinergic with atropine‑like actions, penthienate can be expected to share the usual antimuscarinic adverse effect profile (dry mouth, blurred vision, tachycardia, urinary retention, constipation, and potential confusion in susceptible adults). A chemical description notes it as moderately toxic by ingestion and poisonous by parenteral routes, with decomposition releasing toxic fumes, highlighting that systemic toxicity is plausible at high exposure or overdose.guidechem+2

Acute and chronic toxicity (mother)

No modern LD50 or detailed dose–response data in mammals are readily available for penthienate itself, but its class (synthetic anticholinergics) has narrow therapeutic indices, with acute overdose often presenting with severe anticholinergic syndrome. Chronic use may aggravate glaucoma, precipitate urinary retention in predisposed patients, and worsen gastro‑oesophageal reflux or ileus due to reduced motility, consistent with antimuscarinic pharmacology.wikipedia+1

Reproductive and developmental toxicity

There are no specific data on penthienate in pregnancy or developmental toxicity, and no studies were identified targeting teratogenicity or embryo‑fetal effects. By analogy to other anticholinergics, potential concerns include reduced uteroplacental perfusion in severe maternal tachycardia or hypotension, but these remain theoretical and unsupported by direct evidence for this compound.drugcentral+3

Lactation: transfer and infant exposure (class‑based assessment)

No clinical studies, case reports, or milk level measurements for penthienate in breastfeeding women were identified in accessible sources. General lactation guidance emphasizes that most medicines enter breast milk in small amounts, and anticholinergics are typically avoided when safer alternatives exist, especially if they can affect infant neurologic status or maternal milk supply.breastfeeding+2

Given its quaternary structure, penthienate may have limited oral bioavailability and poor penetration into milk, which theoretically reduces infant exposure. However, absence of human pharmacokinetic and safety data in breastfed infants means any risk assessment must remain cautious and based on class effects rather than direct evidence.drugbank+2

Potential effects on lactation and breastfed infants

Anticholinergics can theoretically reduce prolactin secretion and thereby affect milk production, though robust clinical data are limited and often confounded. In a breastfed infant, inadvertent exposure to antimuscarinics can cause anticholinergic symptoms such as irritability, poor feeding, constipation, urinary retention, flushing, or tachycardia, especially in neonates and premature infants.breastfeeding

Because penthienate is intended for functional gastrointestinal disorders and non‑life‑threatening conditions, the balance of risk and benefit rarely favors its use over better studied alternatives during lactation. If exposure occurs, close monitoring of the infant for feeding difficulties, weight gain, stool and urine output, and signs of anticholinergic toxicity is advisable.breastfeeding

Clinical use in breastfeeding women

Guidance for medicines in breastfeeding recommends choosing agents with short half‑life, extensive clinical experience, and published lactation safety data when possible. In the setting of functional gastrointestinal disorders, other approaches (dietetic measures, non‑anticholinergic antispasmodics with better lactation data, or local therapies) are usually preferred over systemic antimuscarinics like penthienate.breastfeeding

If penthienate is considered essential (e.g., no alternative tolerated), clinicians should use the lowest effective dose, shortest possible duration, and avoid in mothers of premature or medically fragile infants, with informed consent regarding the uncertainty of lactation safety. In selected cases with high concern, temporary interruption of breastfeeding or expressed‑milk discard during short treatment courses could be considered, though this must be balanced against the risks of breastfeeding cessation.breastfeeding

Contraindications and cautions

The Bulgarian Medpedia entry lists hypersensitivity to penthienate or its excipients as a contraindication, consistent with standard product information. As with other anticholinergics, caution is warranted in patients with narrow‑angle glaucoma, urinary outflow obstruction, paralytic ileus, severe ulcerative colitis, and tachyarrhythmias, although these specific warnings are inferred from class rather than directly cited from a penthienate product label.medpedia.framar+2

Given the lack of lactation‑specific labeling, prescribers should integrate general breastfeeding medicine principles, involve the mother in shared decision‑making, and document the rationale when opting for penthienate in a breastfeeding woman.breastfeeding

Practical toxicology–lactology summary

From a toxicology standpoint, penthienate is a moderately toxic synthetic antimuscarinic with atropine‑like effects and standard anticholinergic overdose risks, but with limited modern toxicological characterization. From a lactology perspective, lack of direct evidence, potential for maternal and infant anticholinergic adverse effects, and availability of alternative therapies support classifying penthienate as a drug to avoid or reserve for exceptional situations in breastfeeding.drugs.ncats+3